The Association of Spanish Veterinarians Specializing in Small Animals (AVEPA) recognizes the research on leishmaniosis carried out by Bioiberica Animal Health
The poster on a multicenter study carried out by researchers of the Murcia University, the Complutense University of Madrid, Tufts University and Bioiberica, has received the prize for best free communication presented at the Southern European Veterinary Conference
This investigation demonstrated the efficacy of Impromune for the treatment of canine leishmaniosis
News report published in La Verdad de Murcia
The researchers received the prize of the best free communication presented at the 2016 AVEPA-SEVC Congress, which took place this past October in Granada.
This study proves the clinical efficacy of Impromune for the treatment of canine leishmaniosis, a disease that more than 350 million people in the world are at risk of contracting.
More precisely, the study demonstrated the clinical improvement in dogs with leishmaniosis, as well as a normalization of the serum levels of various acute phase proteins in the patient, which indicates that the patient is responding correctly to the treatment. The treatment consisted of meglumine antimoniate combined with Impromune®, a compound by Bioiberica Animal Health which consists of nucleotides and AHCC. This combination obtained better results than the standard treatment, without being associated with unwelcomed secondary effects.
Related News
This year's winning product was DermalEase/Atopivet drops and mousse - a topical skin care solution.
Pet food is constantly evolving, with new and innovative products being introduced to promote a healthier and more conscious nutrition for pets.
- This marks yet another step forward in the internalisation strategy of this business unit's dedicated to companion animal health
- The company has launched three products for joint and internal health: Condrovet® Force HA, Calmurofel® and Impromune®